跳至主要内容
临床试验/JPRN-jRCTs061190025
JPRN-jRCTs061190025已完成未知

Exploratory study on pharmacokinetics and optimum dosing regimen of cefmetazole, flomoxef and ceftolozane-tazobactam as prophylaxis for surgical site infection by ESBL-producing Escherichia coli after lower gastrointestinal surgery

Ohge Hiroki0 个研究点目标入组 29 人开始时间: 2019年12月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
29

研究概览

简要总结

This study has provided a foothold for clarifying the mechanism of postoperative infection caused by ESBL-producing E. coli, and has also clarified the tissue migration and concentration maintenance of each antimicrobial agent, such as the tendency of CTLZ and TAZ to maintain high concentrations in the peritoneum. We believe that the results of this study will contribute to the prevention of postoperative complications by selecting the optimal antimicrobial agent according to surgical invasion and time requ

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1 Patients scheduled for elective lower gastrointestinal surgery (regardless of open surgery or laparoscopic surgery)
  • gastrointestinal surgery (limited to open surgery cases)
  • 2 Inpatients over 20 years old (include 20 years old) who agree to participate in this study, regardless of gender
  • 3 Patients who can give written informed consent to participate in this study

排除标准

  • 1 Patients with a history of allergies to Cefmetazole, Flomoxef, Ceftolozane/Tazobactam or Metronidazole
  • 2 Patients with a history of allergies to cephems
  • 3 Combined use of
  • 4 Patients who are pregnant or nursing
  • 5 Patients with organic diseases in the brain and spinal cord
  • 6 Patients with renal dysfunction who have creatinine clearance less than 50 ml / min estimated by Cockloft-Gault equation
  • 7 Patients judged inappropriate for this study by the researcher

研究者

发起方
Ohge Hiroki

相似试验